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Dissecting the hemagglutinin head and stalk-specific IgG
antibody response in healthcare workers following pandemic
H1N1 vaccination
Sarah M Tete1,2,3, Florian Krammer4, Sarah Lartey1,2,3, Geir Bredholt1, John Wood5, Steinar Skrede6 and Rebecca J Cox1,2,3
Traditionally, neutralising antibodies that are directed to the major surface glycoprotein hemagglutinin (HA) head domain are
measured as surrogate correlates of protection against influenza. In addition to neutralization, hemagglutinin-specific antibodies
may provide protection by mediating antibody-dependent cellular cytotoxicity (ADCC). During the 2009 pandemic, vaccination
induced HA-specific antibodies that were mostly directed to the conserved HA stalk domain. However, the protective role of these
antibodies has not been investigated in detail. We quantified the HA head and stalk-specific antibodies, their avidity, ability to
neutralise virus and activate natural killer cells in an ADCC assay. We analyzed sera obtained from 14 healthcare workers who had
low hemagglutination inhibition (HI) antibody titres at 3 months after pandemic H1N1 vaccination as well as from 22 controls.
Vaccination resulted in a HA stalk dominant antibody response in both low responders and controls. Revaccination of low
responders, 5 months later, resulted in a boost in antibodies, with HA head-specific antibodies dominating the response.
Comparative analysis of head and stalk antibody avidities revealed that stalk-specific antibodies were qualitatively superior.
Furthermore, stalk-specific antibodies mediated virus neutralization and had significantly higher ADCC activity than head-specific
antibodies. Despite the head and stalk-specific antibodies being lower in low responders, they had comparable antibody avidity,
ADCC functionality and neutralising capacity to those of controls who had high HI titres post-vaccination. Thus, our study has
demonstrated that HA stalk-specific antibodies may have an important role in protection through neutralization and ADCC in low
responders who do not maintain seroprotective HI antibodies.
npj Vaccines (2016) 1, 16001; doi:10.1038/npjvaccines.2016.1; published online 28 July 2016
INTRODUCTION
Influenza pandemics occur at unpredictable intervals when a
novel influenza virus arises which can place a major strain on the
global healthcare system. These pandemic viruses can cause high
levels of severe illness and death. In 2009, an influenza A H1N1
virus strain caused a pandemic that started in Mexico and
California then rapidly spread globally. The pandemic H1N1
(H1N1pdm) strain was antigenically distinct from the recently
circulating seasonal H1N1 strains and the majority of the
population was immunologically naïve to this virus.
Annual influenza vaccination is recommended for healthcare
workers (HCW) so as to maintain the integrity of the healthcare
system, reduce absenteeism and reduce influenza A transmission
to vulnerable patients.1 Vaccination of HCWs has been shown to
protect hospitalised patients as well as decrease influenza-like
illness and mortality in residents of care-facilities.2 During the 2009
pandemic outbreak, the World Health Organization prioritised
HCW for vaccination. H1N1pdm vaccination studies showed that a
single dose of pandemic vaccine elicited protective serum
hemagglutination inhibition (HI) titres in adults, including
HCW.3–8 However, seasonal influenza vaccines did not induce
protection against the novel H1N1pdm virus.9,10
HI antibodies are directed to the major surface glycoprotein,
hemagglutinin (HA), and are the primary correlate of protection.
HA is synthesised as a precursor, HA0, which is then cleaved by
host proteases into disulphide-linked HA1 and HA2 subunits,
activating virus infectivity.11 Antibodies directed to the HA head
domain that is composed of the majority of the HA1 subunit
prevent virus attachment to the sialic acids on host cells. These
antibodies directed to the immunodominant head of the HA have
potent neutralising activity that can be detected by HI or
microneutralization assays. Antibodies directed to the HA stalk
domain, primarily composed of HA2 subunit and the N- and
C-terminal ends of HA1, have other functions, including blocking
viral fusion with the host cell and antibody-dependent cellular
cytotoxicity (ADCC).12
H1N1pdm vaccines preferentially induced HA stalk-specific
antibodies. In contrast, seasonal inactivated vaccines induce strain
specific antibodies directed to the HA head domain and minimal
HA stalk-specific antibodies.13,14 Furthermore, HA stalk antibodies
are postulated to be boosted most efficiently in individuals
previously exposed to HAs whose head domains differ substan-
tially from the infecting novel virus strain. Here, a memory B-cell
response is boosted against the conserved HA stalk domain.15
Importantly, HA stalk-specific antibodies are broadly reactive and
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may have a significant role in protection against infection in the
absence of HA head-specific antibodies.
In this study, we analyzed the magnitude of HA-specific
antibodies induced after adjuvanted pandemic influenza
vaccination in HCW. We also analyzed the quality as well as the
neutralising and ADCC function of HA-specific antibodies in
low-responder HCW who fail to maintain seroprotective HI
responses after H1N1pdm vaccination.
RESULTS
Low responders failed to maintain HI titres post-vaccination
Thirty-six HCW were recruited to the study based on their HI
response and split into two groups; low responders (LRs) who
failed to maintain protective HI titres by 3 months (3M) and a
control group (Figure 1a). Fifty per cent of the controls had
protective HI titres (geometric mean titre (GMT) = 23) before
vaccination in comparison to 1 LR (7%) (GMT= 6). Following
pandemic H1N1 vaccination, HI titres increased significantly by
D21 in both groups (Po0.01). However, in LRs, titres were
significantly lower (GMT= 132) (Po0.001) than controls (GMT=
1,223). All the controls maintained their protective HI titres at
3 mol/l, whereas HI titres decreased below protective levels for all
the LRs (Figure 1b). This decrease may imply that LRs are no
longer protected, although their antibodies may mediate protec-
tion through other mechanisms.
The back-boost of cross-reactive antibodies to pre-pandemic
seasonal H1N1 strains is lower in LRs
The H1N1 strains circulated from 1977 to 2008, when the
H1N1pdm appeared and replaced them as the seasonal
strain. We examined the cross-reactivity of the HI response in 20
controls and 14 LRs to the following historical strains; USSR/77,
Brazil/78, Taiwan/86, Texas/91, New Caledonia/99 and Brisbane/07
(Figure 2).
Interestingly, pre-vaccination, LRs had significantly lower titres
(GMTso40) to all the seasonal H1N1 strains tested in this study
(Po0.05) than the equivalent responses to A/California/07/09.
This was in contrast to controls who had HI GMT440 for all
strains except for the oldest strains (USSR/77 and Brazil/78).
Of the controls, 70–100% had seropositive pre-vaccination titres
to Taiwan/86, Texas/91, New Caledonia/99 and Brisbane/07.
Pre-vaccination sera showed greatest reactivity to Texas/91 in
both controls and LRs with GMT of 137 and 40, respectively.
Pre-vaccination titres to Texas/91 were higher than those
observed to 2009 H1N1pdm.
After pandemic H1N1 vaccination, (D21) sera cross-reacted with
all the seasonal H1N1 strains in controls with seroprotective titres
in 80–100% of subjects. Back-boosting, with HI titres greater or
comparable to those to H1N1pdm, was induced for Texas/91 and
Figure 1. Study outline. (a) Thirty-six HCW received the AS03 adjuvanted monovalent pandemic influenza vaccine in 2009. Serum samples
were collected before vaccination (D0); D21, 21 days, 3M and 6M post-vaccination. On the basis of HI titres at 3M, 14 HCW who did not have
seroprotective titres (low responders) were offered revaccination. 12 HCW were revaccinated 5M after the first vaccination. Additional serum
samples were collected at time of revaccination (5M) and 21 days later (+D21) in low responders. (b) HI titres against influenza A H1N1pdm
virus at D0, D21 and 3M. The dotted line indicates a titre of 40, which is considered protective. * indicates statistically significant differences in
responses Po0.05; **Po0.01; ***Po0.001.
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Figure 2. HI titres to previous seasonal H1N1 viruses. The HI assay
was used to examine the cross-reactive HI responses at D0 and D21
against six historical H1N1 virus strains; A/USSR/90/77 (USSR),
A/Brazil/11/1978 (Brazil), A/Taiwan/1/86 (Taiwan), A/Texas/36/91
(Texas), A/New Caledonia/20/99 (NC) and A/Brisbane/59/07 (Bris).
The HI response to the H1N1pdm(Cal) virus is shown in the last
column. The black circles represent the GMTs for controls, whereas
the blue triangles represent the GMTs for LRs. The error bars on the
plot show the lower and upper extremes. *Po0.05; **Po0.01;
***Po0.001, ****Po0.0001.
Influenza hemagglutinin head and stalk antibodies
SM Tete et al
2
npj Vaccines (2016) 16001 Published in partnership with the Sealy Center for Vaccine Development
Taiwan/86 with GMTs of 1,841 and 618, respectively. In
comparison to controls, cross-reactive antibodies in LRs were
significantly lower to 4 of the 6 strains; USSR/77, Brazil/78, Taiwan/
86 and Texas/91 (Po0.05). At D21, the GMTs to USSR/77 and
Brazil/78 were low at 23 and 33, respectively, whereas for the 4
other seasonal H1N1 strains titres were 440 (range: 69–442).
Seroprotection was lower in LRs (42–92%) compared to controls,
with the highest seroprotective titres observed for the Texas/91
strain. In summary, these results show that H1N1 cross-reactivity
of post-H1N1pdm vaccination sera to seasonal H1N1 strains is
reduced in LRs.
HA stalk-specific IgG antibodies dominate the response to
pandemic H1N1
We dissected the specificity of the antibodies to the different HA
domains, which may have different functions in controlling
infection. Sera were evaluated for antibodies specific for the
H1N1pdm whole HA, HA1 (head domain) and chimeric HA
construct, cH6/1 (stalk domain).
Pre-vaccination, antibodies specific to the whole HA were
significantly lower in LRs compared to controls (Po0.05).
Vaccination resulted in an increase in these antibodies, however
to a lesser magnitude than in controls (Figure 3a). The antibody
levels induced by vaccination were significantly lower in LRs
compared to controls to both the HA head and the stalk domains.
In controls, both the HA head and stalk-specific antibodies
increased significantly after vaccination (Po0.01). However, in
the LRs only stalk-specific antibodies increased significantly
(Po0.001), whereas HA head-specific antibodies remained low.
The fold increase in HA stalk-specific antibodies was comparable
between the two groups, whereas controls had a higher fold
increase in HA head-specific antibodies (Po0.01) (Figure 3b).
HA stalk-specific antibodies dominated the response pre- and
post-vaccination in both groups (Figure 3c). There was a
significant increase in the proportion of HA stalk antibodies at
D21 in comparison to pre-vaccination ratios in LRs (Po0.05).
Pre-vaccination, 75% of controls had HA stalk dominant IgG
antibodies, whereas at D21, 82% had a HA stalk dominant IgG
antibodies. However, in LRs, there was an increase from 57 to 85%
in number of participants with stalk dominant antibody responses
at D0 and D21, respectively (Figure 3c).
Revaccination of LRs boosts the HA head-specific antibodies
Next, we analysed the kinetics of the HA-specific IgG antibodies in
LRs following revaccination with the AS03 adjuvanted monovalent
pandemic H1N1 vaccine. After revaccination, the HA head was no
longer novel so we expected a boost of the response to HA head
domain. As we did not collect sera from controls at the time of LR
revaccination (5M), we used sera collected at 6M for comparison
purposes. IgG antibodies specific to the whole HA where
maintained for at least 6M in controls but not in LRs where they
decreased to pre-vaccination levels. However, revaccination of LRs
resulted in a boost in the whole HA-specific antibodies (Po0.01)
(Figure 4a).
In controls, the HA head-specific IgG antibodies decreased to
pre-vaccination levels by 6M. Similarly, in LRs, HA head-specific
IgG antibodies returned to pre-vaccination levels at the time of
revaccination (5M). The level of these HA1 specific IgG antibodies
was significantly lower in the LR group at 5M (Po0.001)
(Figure 4b). In contrast to HA head-specific antibodies that
decreased by 6M post-vaccination, HA stalk-specific antibodies
were maintained for at least 6M in controls. However, in LRs,
Figure 3. Hemagglutinin-specific IgG antibody responses. (a) IgG titres specific to the whole HA (Cal09), HA head domain (HA1) and stalk
domain (CH6/1) at D0 and D21 after vaccination in controls (black circles) and low responders (grey triangles). (b) Fold change in specific IgG
titres calculated as D21 titres÷D0 titres. (c) Bar chart shows the ratio of HA stalk-specific antibodies to HA head-specific antibodies at D0 and
D21. Bars show mean and error bars show s.d. Pie charts with the proportion of controls (black) and LRs (grey) who have stalk dominant IgG
antibody responses. The white pieces of the pie show the proportion of HCW with HA head dominated or equal HA head and stalk dominated
IgG response. *Po0.05; **Po0.01; ***Po0.001, ****Po0.0001.
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HA stalk-specific antibodies were significantly lower than
controls (Po0.001) and decreased to pre-vaccination levels 5M
post-vaccination (Figure 4c).
Revaccination boosted both the HA head and HA stalk-specific
IgG response by D21 (Po0.01). After the first vaccination, the IgG
titres increased mostly to the HA stalk, in contrast revaccination
induced antibody responses mostly to the HA head (Figure 4d).
Twenty-one days after the first vaccination, there was higher fold
increase in HA stalk-specific IgG than HA head-specific IgG titres.
However, following revaccination, there was a significantly higher
fold increase in IgG titres to the HA head than after the first
vaccination (Po0.001).
Figure 4. Hemagglutinin-specific IgG antibody responses following revaccination. IgG titres specific to the (a) whole HA, (b) HA head domain
and (c) HA stalk domain at 6M in controls (black circles) and 5M (revaccination) (grey triangles) and 21 days after revaccination (+D21) (open
triangles) in LRs. (d) The bar chart shows fold induction of IgG titres at D21 post-vaccination over D0 titres. Mean fold induction is shown as
bars and grey triangles represent each individual’s fold induction after the first vaccination (D21/D0), whereas fold induction 21 days after
revaccination is shown in open triangles (+D21/5M). **Po0.01; ***Po0.001.





















Controls       LRs



















Controls       LRs
Figure 5. Hemagglutinin-specific IgG antibody avidity. Avidity of (a) HA head domain specific and (b) HA stalk-specific IgG at D0 and D21
post-vaccination. Avidity index was calculated as the percentage of HA-specific IgG antibodies remaining bound after 1.5 nmol/l NaSCN
treatment measured as (absorbance of treated samples÷absorbance of untreated samples) × 100%. *Po0.05; **Po0.01.
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HA stalk-specific IgG antibodies show avidity superior to HA
head-specific antibodies
To evaluate the quality of the antibodies in the controls and LRs,
we measured the avidity of HA head and HA stalk-specific IgG
antibodies in these two cohorts of HCW. The avidity of HA-specific
IgG antibodies was measured in an avidity enzyme-linked
immunosorbent assay (ELISA) using NaSCN as a chaotropic agent.
Untreated sera were compared to those treated with 1.5 mol/l
NaSCN, and the percentage of bound IgG antibodies remaining
after 1.5 mol/l NaSCN treatment was calculated. At baseline,
the avidity of head-specific antibodies was low. The avidity of
head-specific antibodies increased significantly in both controls
and LRs following vaccination (Po0.05) (Figure 5a). In controls,
the avidity index increased from a mean of 3.02–7.11% at D21.
In LRs, an increase from a mean of 1.95–8.14% was observed
post-vaccination.
The avidity of HA stalk-specific antibodies was significantly
higher than that of HA head-specific antibodies at both time-
points (Figure 5b). In controls, the % of IgG antibodies remaining
bound after NaSCN treatment was 25.74% (range: 5.3–69%) at
baseline. Vaccination resulted in a significant increase in the
avidity of HA stalk-specific IgG antibodies in LRs only. The avidity
index of the IgG antibodies increased from 25.40% (range:
7.46–55.92%) at baseline to 30.82% (range: 17.13–65.26%) at
D21 post-vaccination in LRs (Po0.01). Despite, the quantity of the
stalk-specific antibodies being lower in LRs compared to controls,
the antibodies displayed equivalent avidity at both time-points.
HA stalk-specific antibodies can neutralise virus in the absence of
HI antibodies
To assess the in vitro functionality of H1 HA stalk-specific
antibodies, we performed a microneutralization assay with a virus
that expresses a cH9/1 HA and an irrelevant N3 neuraminidase.
The HA stalk domain of this virus is derived from H1, and the HA
head domain is from H9. Subjects in this study are expected to be
naive to the avian H9 and N3 in this virus. No standard virus
neutralization titre for 50% protection has been recognised.
However, a previous study in H1N1pdm-infected adults showed
that the MN titre was generally twofold higher than the HI titre
when the HI titre was ⩽ 160.16 We therefore used a threshold of
80 to define protective titres. H1 HA stalk-specific neutralising
antibodies were detected pre-vaccination when the majority of
controls (50%) and LRs (93%) had HI titreso40 (Figure 6a). These
H1 HA stalk-specific neutralising antibodies were present in all
subjects with GMT of 204 and 171.5 in controls and LRs,
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Figure 6. Hemagglutinin-specific antibodies functionality in neutralization and ADCC. (a) H1 HA stalk-specific neutralizing antibodies.
Geometric mean titres of neutralizing antibodies against cH9/1 N3 virus with H1 HA stalk domain, irrelevant neuraminidase and H9 HA head
domain in 10 controls (circles) and 10 low responders (triangles). The frequency of INF-γ expression and CD107a by NK cells to (b) HA head
domain (HA1) and (c) stalk domain (CH6/1) in the presence of sera diluted 1:10 at D0 and D21 after vaccination in 10 controls and 10 low
responders. (d) INF-γ and (e) CD107a expression mediated by HA head-specific antibodies and HA stalk-specific antibodies was compared for
each sample sera standardized in an ELISA to give OD of 0.7± 0.2. *Po0.05; **Po0.01.
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respectively. Vaccination resulted in a significant increase in HA
stalk-specific neutralising antibodies in LR (Po0.05) but not in
controls.
HA stalk-specific antibodies are better mediators of natural killer
(NK) cell activation
As the HA-specific antibody response was dominated by HA
stalk-specific antibodies, we wanted to determine the functionality
and possible protective mechanisms of these antibodies,
especially in LRs where HA head-specific antibodies were low.
We therefore assessed the ADCC induced by HA head and HA
stalk-specific antibodies using an NK activation assay measuring
CD107a (degranulation) and INF-γ expression by flow cytometry.
The gating strategy for flow cytometry is shown in Supplementary
Figure S1. We used sera diluted 1:10 rather than endpoint titres as
a positive correlation between NK cell activation at a single sera
dilution of 1:10 and NK activation end point titre has been
previously shown.17 Pre-vaccination, NK cell activation was
mediated by both HA head and HA stalk-specific antibodies and
the levels of NK cell activation were comparable between LRs and
controls. Vaccination resulted in increased NK cell activation with a
significant increase in head and stalk antibody-mediated CD107a
expression being observed for both LRs and controls (Po0.01)
(Figure 6b,c). However, the levels of INF-γ expression mediated by
HA head-specific antibodies did not increase for either LRs or
controls. In contrast to controls who had an increase in INF-γ
expression at D21, no change in HA stalk antibody-mediated INF-γ
expression was detected in LRs (Figure 6c).
In order to make a direct comparison of the levels of
head versus stalk antibody-mediated NK cell activation, we
standardized sera in an ELISA assay to give an optical density
(OD) of 0.7 ± 0.2. In controls, pre-vaccination HA head and HA
stalk-specific antibodies induced similar NK cell expression of
INF-γ (Figure 6d). However, post-vaccination, HA stalk-specific
antibodies induced significantly higher INF-γ expression than
head-specific antibodies in controls (Po0.01). In contrast, LRs’ HA
stalk-specific antibodies induced significantly higher INF-γ
expression at D0 than head-specific antibodies (Po0.05), whereas
at D21 the INF-γ expression levels were maintained. Pre-
vaccination, HA stalk-specific antibodies induced significantly
higher NK cell CD107a expression than HA head-specific
antibodies in both LRs and controls (Figure 6e). Post-vaccination,
only HA head-specific antibodies from LRs had an increased ADCC
activity as measured by CD107a expression. Despite no increase in
CD107a expression at D21, the HA stalk-specific antibodies
maintained a significantly higher ADCC induction than HA
head-specific antibodies in both LRs and controls (Po0.01).
Furthermore, there was no significant difference in the ADCC
mediated by both head and stalk-specific antibodies between LRs
and controls. Interestingly, there was no correlation between NK
cell activation and HI titres in controls (data not shown). However,
in LRs, HI titres negatively correlated with NK cell INF-γ expression
mediated by both HA head and HA stalk antibodies (Po0.01).
This suggests that H1N1pdm vaccination induced HA-specific
antibodies that can mediate FcγR-dependent NK cell activation,
regardless of HI antibodies.
DISCUSSION
The H1N1pdm virus contained a novel HA head domain that was
different from the pre-pandemic seasonal H1 viruses. Pandemic
vaccination induced antibodies that were directed towards
the immunosubdominant conserved epitopes on the HA stalk
domain.13,14
In the current study, we aimed to investigate and to increase
understanding of the HA-specific IgG responses of LR HCW
following 2009 pandemic influenza A (H1N1) vaccination. We used
chimeric HA constructs to differentiate between the response to
the HA head and stalk domains as these antibodies may have
different functions in controlling influenza infection. Influenza
specific responses are commonly measured by the HI assay. HI
antibodies are a correlate of protection, and are mostly directed to
the HA head domain and do not necessarily reflect the entire
spectrum of vaccine induced antibodies. We demonstrated that
LRs IgG antibodies were quantitatively inferior to controls but
qualitatively similar.
We showed that a single dose of AS03 adjuvanted pandemic
H1N1 vaccine elicited a significant HI response in controls that was
maintained by 3M post-vaccination, whereas in LRs the response
was lower and waned by 3M. The lower HI response may be
attributed to the lower quantities of HA head-specific antibodies
in LRs as antibodies measured by the HI assay are predominantly
HA head-specific.
Back-boosting, where a substantial response to older viruses is
induced, depending on pre-exposure has been recently described
for both H3N2 and H1N1 viruses.18,19 Li et al.18 showed sera from
H1N1pdm-infected people had considerable cross-reactivity with
H1N1 strains from 1984 to 1994. They showed that the back-boost
for H1N1 was due to a shared epitope in the head domain at
H1N1pdm and most seasonal H1N1 strains from 1983 to 1996.
HAs of most seasonal H1N1 between 1983 and 1996 contained a
K133 amino acid at Sa antigenic site of HA, but not H1N1 viruses
before 1983 or after 1996. Our results are in agreement with this
as we showed back-boost of HI against viruses up to Texas/91 but
not much against NC/99 and Brisbane/07. LRs had a lower back-
boost of cross-reactive HI antibodies to pre-pandemic, seasonal
H1N1 strains. This may be due to differences in exposure history to
different H1N1 strains or due to limited induction of HI antibodies
that bind to shared epitopes on the HA of pandemic and seasonal
H1N1 strains. Moreover, the pandemic vaccine may have elicited
antibodies with broader specificities that bind the same epitopes
as antibodies induced by seasonal H1N1 strains as well as to
additional epitopes. Despite the lower HI antibodies detected in
the LR cohort, HA stalk-specific antibodies may also provide an
alternative method of protection.
We tested for the HA domain binding of IgG antibodies and
found that HA stalk-specific antibodies were lower pre-vaccination
in LRs, possibly due to differences in the priming or infection
history between controls and LRs or due to the characteristics of
the HA-specific memory previously generated. Even though
pre-vaccination HA stalk-specific antibodies were lower, a single
dose of H1N1pdm vaccine elicited significant stalk-specific
antibodies more efficiently than HA head-specific antibodies.
However, 5M post-vaccination, HA head and stalk-specific
antibodies in LRs had decreased and were significantly lower
than those in controls. Although none of the HCW reported
H1N1pdm infection, it cannot be ruled out that some controls had
exposure or subclinical infection between the 5M and 6M interval.
Alternatively, the lower antibodies in LR could be explained by
poor antibody maintenance in this cohort. The decreased
antibody titres may not necessarily mean that the HCW were no
longer protected, as factors other than antibody titres may be
important in long-term protection.
These findings raise questions as to: (i) why the conserved HA
stalk domain shows superior immunogenicity after H1N1pdm
vaccination, whereas after seasonal vaccination the HA head-
specific response dominates20,21; and (ii) the effect of homologous
boosting on HA domain binding. We found a significantly higher
boost in head than stalk-specific antibodies following revaccina-
tion of LRs. This is in line with previous reports following
H1N1pdm and H5N1 vaccination.22,23 Ellebedy et al. demonstrated
that the first dose of H5N1 vaccination elicited a stronger
stalk-specific response than head-specific response. However,
booster vaccination resulted in a vigorous head-specific response
and marginal increase in stalk-specific antibodies.23 These findings
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support the theory that at the time of the first vaccination,
vaccinees had negligible pre-existing memory B cells specific to
the immunodominant HA head domain in comparison with stalk-
specific ones. The strong stalk-specific antibody response likely
reflects the reactivation of stalk-specific memory B cells generated
by previous seasonal H1N1 infections. Accordingly, memory B cells
specific for the immunosubdominant HA stalk were recruited and
reactivated in the absence of competition from memory B cells
specific for the immunodominant HA head domain. A primary
antibody response was also induced to the HA head domain
resulting in the increase in plasmablasts and memory B cells
generation. Upon booster vaccination, the recently generated
head-specific memory B cells out-competed the stalk-specific
memory B cells.24
The quality of antibodies is important for their functionality. In
our analysis, HA stalk-specific antibodies not only dominated the
response but also displayed superior avidity to head-specific
antibodies. These results are in agreement with the findings of
He et al.,20 who showed that plasmablast-derived polyclonal
antibodies from elderly (470 years) after H1N1pdm vaccination
had higher avidity than those from young (18–32 years) and that
HA2 specific antibodies had higher avidity than HA1 specific
antibodies. The higher avidity of stalk-specific antibodies could be
explained by antibody secreting cells producing these antibodies
being derivatives of memory B cells from previous H1N1
encounters that have gone through several rounds of selection
and affinity maturation.25,26As the 2009 pandemic H1N1 con-
tained a novel head, different from the pre-pandemic seasonal
H1N1 viruses, most of the HA head-specific antibodies would have
been generated from antibody secreting cells from a primary
immune response that contain few somatic mutations, explaining
the lower avidity of HA head-specific antibodies. It has been
shown that broadly cross-reactive HA-specific antibodies that
exhibit high levels of somatic hypermutation are induced after
H1N1pdm vaccination or infection.13,27 Analysis of the somatic
mutation status of the immunoglobulin genes from the memory B
cells or plasmablasts specific for the HA head and stalk domains is
required to give insight into the origin of the response in our
cohort of HCW. These high-avidity HA stalk-specific antibodies
may have an important role in protecting these LRs in the absence
of HI antibodies. However, a correlate of protection for these
antibodies remains to be determined.
We showed that high titres neutralising HA stalk-specific
antibodies were present in all subjects pre-vaccination, when HI
antibodies were absent or low in the majority of the HCW. The
neutralising stalk-specific antibodies were maintained in controls
and only increased significantly in LRs after vaccination.
These neutralising stalk-specific antibodies could be protective
regardless of the HI titre and could have a significant role in
protecting the low responders who have significant quantities of
HA stalk-specific antibodies.
In addition to virus neutralization, HA-specific antibodies can
bind to infected cells and activate NK cells through FcγR resulting
in lysis of target cells and secretion of cytokines like INF-γ.17
In this study, we showed that ADCC antibodies were present
pre-vaccination when the majority of the subjects were HI
seronegative and these ADCC antibodies were mostly directed
towards the HA stalk domain. These pre-existing ADCC antibodies
may assist in clearance of H1N1pdm virus infection.
Post-vaccination, the HA stalk-specific antibodies were better
mediators of ADCC than HA head-specific antibodies. This
difference in the ADCC activity between HA head and
stalk-specific antibodies may be attributed to the relative
difference in affinities of these antibodies for HA. Despite LRs
having lower post-vaccination HI titres and lower HA-specific IgG
titres than controls; their antibodies had comparable ability to
mediate NK cell activation. We found no correlation between HI
titre and NK cell activation in controls, whereas in LRs INF-γ
expression negatively correlated with HI titres. Our results are
similar to a previous report that found no correlation between HI
titres and HA-specific ADCC antibodies.17 However, these authors
characterised the response induced by antibodies that bound to
the whole HA protein, whereas we dissected between HA head
and stalk-specific antibodies. Of note, the HI and ADCC assays
measure different aspects of antibody function. HI assay assesses
the binding of the antibody through its Fab region to antigen,
whereas the ADCC assay assesses the NK activation by antibodies
bound through their Fc region. Fc–FcγR interactions are required
for the protection by HA stalk-specific antibodies suggesting a role
of ADCC antibodies in protection.28–30 Furthermore, cross-reactive
ADCC antibodies to influenza virus have been reported in the
absence of neutralising antibodies.31 Thus, it is likely that HA
stalk-specific antibodies may provide alternative protection in this
cohort of LRs where HA head-specific antibodies are low and
induced short-term protection as measured by the HI assay. This
underlines a possible limitation of using HI titre as a sole predictive
correlate of protection.
In summary, the characterisation of the HA stalk-specific
antibodies denotes an important step in understanding the
protective capacity of these antibodies. Further analysis of the HA
stalk-specific antibody repertoire and function would facilitate
rational vaccine design. In LRs where the HI responses are poor,
vaccination strategies could potentially aim to induce HA
stalk-specific antibodies. The lower quantity of HA-specific
antibodies could be compensated for by the higher avidity of
HA stalk-specific antibodies that have better ADCC functionality
as well as neutralising capacity. Enhancing the amount of HA
stalk-specific antibodies elicited by vaccination or booster
vaccination should be considered in LR HCW. These antibodies
could provide broad cross-protection and could be used for
immunological priming of the general population to quickly
respond to a future pandemic influenza threat.
MATERIALS AND METHODS
Study design and participants
The HCWs were vaccinated in October 2009 at the Haukeland University
Hospital (HUH, Bergen, Norway) with a single dose of the monovalent
pandemic H1N1 vaccine (Pandemrix) adjuvanted AS03 (GlaxoSmithKline
(GSK), Wavre, Belgium).
Thirty-six HCW were retrospectively selected by their HI antibody
response at 3M after pandemic H1N1 vaccination. On this basis, a cohort of
14 LRs who failed to respond or maintain a protective HI antibody
response (titre⩾ 40) at 3M after vaccination were selected. As a control
group, 22 HCW who maintained a protective HI antibody response were
selected. LRs were offered a second dose of vaccine, and 12 participants
were revaccinated 5M later. Sera were collected at vaccination, day 21
(D21), 3M, and 6M post-vaccination in controls. In revaccinated LRs,
additional sera were collected at revaccination (5M) and 21 days later
(Figure 1a). The inclusion and exclusion criteria for this study are described
elsewhere.7 All participants provided written informed consent before
inclusion in the study, which had ethical and regulatory approval
(ClinicalTrials.gov NOT01003288).
HI assay
Serum samples were treated with receptor destroying enzyme and run in
the HI assay twice in duplicate using turkey red blood cells as previously
described.7 HI responses were analyzed against the homologous pandemic
H1N1 virus strain, A/California/07/09, and against six prototype seasonal
H1N1 strains; A/USSR/90/77, A/Brazil/11/78, A/Taiwan/1/86, A/Texas/36/91,
A/New Caledonia/20/99 and A/Brisbane/59/07. Seroprotection was defined
as an HI titre ⩾ 40. Titreso10 were assigned a value of 5 for calculation
purposes.
Anti-HA IgG ELISA
Sera were evaluated in duplicate for IgG antibodies.32 The plates were
coated with influenza whole HA, HA1 (A/California/06/2009(H1N1))
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hexahistidine-tagged (eEnzyme, IA-01SW-005P) or cH6/1, a chimeric HA
(cHA) that combines H1 stalk domain with globular head domain derived
from H6 influenza A virus.33 The antibody concentrations were calculated
as endpoint titres that were determined when the reactivity of the diluted
sample reached background levels.
Anti-HA IgG avidity ELISA
Sera were evaluated for avidity of antibodies against influenza HA1
(A/California/06/2009(H1N1)) hexahistidine-tagged (eEnzyme, Gaithers-
burg, MD, USA) and cH6/1.34 Sera were first diluted in duplicate to the
appropriate OD of 0.7 ± 0.3 in a direct ELISA and 1.5 mol/l sodium
thiocyanate (NaSCN) (Sigma, St Louis, MO, USA) was added 1 h after the
sera, followed by 1 h incubation. The avidity index calculated as: (OD450
treated serum/OD450 untreated serum) × 100%.
Virus neutralization assay
Expansion of MDCK cells. Madin-Darby Canine Kidney (MDCK) (ATCC,
Manassas, VA, USA, CCL-34) were cultivated in DMEM supplemented with
10% fetal bovine serum (FBS) and 1× Penicillin/Streptomycin. MDCK cells
in log-phase growth were plated in 96-well plates such that they are 70–
90% confluent at the time of inoculation. Serum samples were heat-
inactivated at 56 °C for 30 min and run in duplicate. The serum samples
were then diluted 2 fold in virus growth medium containing Dulbecco’s
Modified Eagle’s Medium with tosyl phenylalanyl chloromethyl ketone-
trypsin, 0.14% bovine serum albumin, 100 units/ml penicillin, 100 μg/ml
streptomycin and 0.25 μg/ml amphotericin B. Chimeric 9/1N3 virus was
diluted to 50% tissue culture infectious dose (TCID50) of 100 per 50 μl in
virus growth medium. Fifty microliters of diluted sera was incubated with
50 μl of virus for 1 h at 37 °C. MDCK cells were washed once with
phosphate-buffered solution (PBS) and 100 μl of serum-virus mixture was
added to the cells. Cells were incubated at 37 °C for 1 h then washed once
with PBS before 50 μl of diluted serum and 50 μl of virus growth medium
were added to each well. Infected MDCK cells were incubated for 72 h at
37 °C. Fifty microliters of the supernatant was transferred to a 96-well V
bottom plate and 50 μl of 0.7% turkey red blood cells added.
Hemagglutination activity was measured to detect the endpoint of
agglutination.
ADCC NK cell activation assay
The ADCC assay measuring intracellular NK cell IFNγ and CD107a
expression was conducted as previously described with minor
modifications.35 Briefly, 96-well plates were coated overnight at 4 °C with
1 μg/ml HA1 (A/California/06/2009(H1N1)) 6 ×His tagged (eEnzyme, USA)
or chimeric cH6/1 in PBS. Plates were washed with PBS and incubated with
heat-inactivated human sera for 2 h at 37 °C. After washing, 105 CD16 176v
NK-92 cells (mycoplasma-free, human NK cell line expressing high affinity
176V variant CD16 receptor) (kindly provided by Fox Chase Cancer Center,
Philadelphia, PA, USA) were added per test well. As a negative control for
each sample, NK-92 cells (lacking expression of CD16) were added to an
additional well. The cells were incubated for 16 h at 37 °C with anti-
CD107a-AF488 antibody (Biolegend, San Diego, CA, USA, 328610),
Brefeldin A (5 μg/ml, BD) and monensin (5 μg/ml, BD). Cells were stained
with LIVE/DEAD Fixable Aqua dead cell staining kit (Invitrogen, Carlsbad,
CA, USA), anti-CD3-PE CF594 (BD, Franklin Lakes, NJ, USA, 562280) and anti-
CD56-APC (BD, 555518) before intracellular staining with anti-IFN-γ-BV-421
(Biolegend, 502532). Cells were acquired on BD Fortessa (San Jose, CA,
USA). Data analysis was done using FlowJo version 10 (treeStar, Ashland,
OR, USA).
Statistics
Two-tailed unpaired nonparametric Mann–Whitney tests and paired
nonparametric Wilcoxon tests were performed using GraphPad Prism 6
(Graphpad, La Jolla, CA, USA). A P-valueo0.05 was considered statistically
significant.
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